To hear about similar clinical trials, please enter your email below

Trial Title: Rowing Following Breast Cancer Chemotherapy

NCT ID: NCT05848141

Condition: Breast Cancer Survivors

Conditions: Official terms:
Breast Neoplasms

Study type: Interventional

Study phase: N/A

Overall status: Recruiting

Study design:

Allocation: Randomized

Intervention model: Parallel Assignment

Primary purpose: Prevention

Masking: Single (Outcomes Assessor)

Intervention:

Intervention type: Behavioral
Intervention name: Exercise training
Description: This is a single site center-based supervised exercise intervention.
Arm group label: Indoor Rowing

Summary: There are more than 3.8 million breast cancer survivors in the United States and cancer survivors have a higher risk of cardiovascular disease (CVD) due to chemotherapy than adults without cancer. Cardiovascular rehabilitation can be an effective strategy to decrease the incidence of CVD and its risk factors in this population. The proposed study may help to examine the effect of a novel exercise intervention on cardiovascular rehabilitation in breast cancer survivors.

Criteria for eligibility:
Criteria:
Inclusion Criteria: - diagnosis of primary invasive non-metastatic breast cancer, stages I-III - female based on biological sex - 40 to 80 years of age - completed breast cancer treatment 6 to 24 months prior to study enrollment. Adjuvant endocrine therapy for breast cancer (e.g., ovarian suppression, SERMs, SERDs, AIs), CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy and bisphosphonates are allowed within 6 months prior to study enrollment and during study participation - absence of contraindications to exercise or study participation - study clinician approval Exclusion Criteria: - do not meet inclusion criteria - receiving or scheduled to receive treatment for breast cancer (i.e., chemotherapy, surgery, or radiation) during study participation is not allowed. Adjuvant endocrine therapy, CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy and bisphosphonates are allowed during study participation - lymphedema stage ≥ 2 prior to study enrolment - any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent) - current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss) - consistent participation in ≥150 min/week of moderate-intensity rowing exercise training in previous 6 months

Gender: Female

Minimum age: 40 Years

Maximum age: 80 Years

Healthy volunteers: No

Locations:

Facility:
Name: Integrative Cardiovasculal Physiology Laboratory, University of Florida

Address:
City: Gainesville
Zip: 32611
Country: United States

Status: Recruiting

Contact:
Last name: Demetra Christou, PhD

Phone: 352-294-1746
Email: ddchristou@ufl.edu

Start date: February 26, 2024

Completion date: May 31, 2026

Lead sponsor:
Agency: University of Florida
Agency class: Other

Source: University of Florida

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05848141

Login to your account

Did you forget your password?